Profil bibliographique

Yu Zhu

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
12Citations signalées
3Affiliations récentes

Les institutions déclarées

Shanghai Jiao Tong UniversityRuijin HospitalFudan University Shanghai Cancer Center

Les domaines associés

Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and BiomarkersEpigenetics and DNA MethylationRenal cell carcinoma treatment

Les publications récentes

Accès ouvert 2025 article OpenAlex

Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study

Zhaopei Liu, Kaifeng Jin, Zhen-Bin Xu, Han Zeng et autres

INTRODUCTION: Disitamab Vedotin (DV), a HER-2-targeting antibody-drug conjugate, has exhibited substantial clinical advantages in individuals with metastatic urothelial carcinoma (mUC). Nonetheless, the extent of therapeutic efficacy in real-world scenarios for mUC patients and the specific patient profiles with the most benefit from …

cn (code pays fourni par la source)

4 citations BMC Cancer
Accès ouvert 2025 article OpenAlex

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

Kaifeng Jin, Yawei Ding, Jingtong Xu, Zhaopei Liu et autres

Background The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of TP53 pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and …

cn (code pays fourni par la source)

5 citations Journal for ImmunoTherapy of Cancer
Accès ouvert 2023 article OpenAlex

Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene KDM6A mutation

Zhaopei Liu, Kaifeng Jin, Ziyue Xu, Jingtong Xu et autres

Objective KDM6A, a representative tumour suppressor gene with sex bias, is frequently altered in urothelial carcinoma (UC). The specific impacts of KDM6A mutations on gender-based clinical outcomes in UC remain poorly understood. Methods and analysis We enrolled 2438 patients with UC from …

cn (code pays fourni par la source)

3 citations BMJ Oncology
Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.